Rossella Elisei

36.4k total citations · 7 hit papers
370 papers, 23.3k citations indexed

About

Rossella Elisei is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Oncology. According to data from OpenAlex, Rossella Elisei has authored 370 papers receiving a total of 23.3k indexed citations (citations by other indexed papers that have themselves been cited), including 313 papers in Endocrinology, Diabetes and Metabolism, 80 papers in Surgery and 76 papers in Oncology. Recurrent topics in Rossella Elisei's work include Thyroid Cancer Diagnosis and Treatment (301 papers), Thyroid and Parathyroid Surgery (58 papers) and Thyroid Disorders and Treatments (48 papers). Rossella Elisei is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (301 papers), Thyroid and Parathyroid Surgery (58 papers) and Thyroid Disorders and Treatments (48 papers). Rossella Elisei collaborates with scholars based in Italy, United States and France. Rossella Elisei's co-authors include Furio Pacini, Aldo Pinchera, Martin Schlumberger, Cristina Romei, Fulvio Basolo, Eleonora Molinaro, Paolo Miccoli, Henning Dralle, Johannes W. A. Smit and Laura Agate and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

Rossella Elisei

353 papers receiving 22.7k citations

Hit Papers

European consensus for the management of patients with di... 2006 2026 2012 2019 2006 2015 2015 2014 2011 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
    2006 1.5k citations Furio Pacini, Martin Schlumberger et al. profile →
  2. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
    2015 1.4k citations Samuel A. Wells, L. Sylvia et al. Thyroid profile →
  3. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
    2015 1.4k citations Martin Schlumberger, Makoto Tahara et al. profile →
  4. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    2014 1.2k citations Marcia S. Brose, Barbara Jarząb et al. profile →
  5. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
    2011 1.1k citations Samuel A. Wells, Bruce G. Robinson et al. Journal of Clinical Oncology profile →
  6. Cabozantinib in Progressive Medullary Thyroid Cancer
    2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →
  7. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
    2017 347 citations Eleonora Molinaro, Cristina Romei et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rossella Elisei Italy 72 18.4k 6.2k 5.5k 4.5k 3.6k 370 23.3k
Bryan R. Haugen United States 53 23.6k 1.3× 12.4k 2.0× 3.4k 0.6× 3.9k 0.9× 2.7k 0.8× 159 27.7k
Yuri E. Nikiforov United States 82 26.3k 1.4× 9.9k 1.6× 6.9k 1.2× 7.3k 1.6× 2.6k 0.7× 250 32.8k
James A. Fagin United States 76 15.1k 0.8× 3.2k 0.5× 7.8k 1.4× 8.8k 2.0× 1.6k 0.5× 242 23.5k
Electron Kebebew United States 69 9.8k 0.5× 7.7k 1.2× 4.3k 0.8× 3.8k 0.8× 3.3k 0.9× 378 19.1k
R. Michael Tuttle United States 76 30.7k 1.7× 17.0k 2.7× 4.0k 0.7× 3.1k 0.7× 3.4k 0.9× 326 34.1k
Orlo H. Clark United States 71 9.6k 0.5× 7.2k 1.2× 3.7k 0.7× 3.0k 0.7× 2.1k 0.6× 347 17.1k
Keith C. Bible United States 39 11.5k 0.6× 6.1k 1.0× 3.0k 0.5× 2.4k 0.5× 1.4k 0.4× 94 15.0k
Paolo Miccoli Italy 65 9.3k 0.5× 7.3k 1.2× 3.0k 0.5× 2.4k 0.5× 1.6k 0.4× 390 15.1k
Clive S. Grant United States 77 8.7k 0.5× 9.7k 1.6× 5.3k 1.0× 1.6k 0.3× 3.8k 1.1× 261 19.4k
Sophie Leboulleux France 63 9.6k 0.5× 6.0k 1.0× 2.7k 0.5× 1.2k 0.3× 2.4k 0.7× 260 13.6k

Countries citing papers authored by Rossella Elisei

Since Specialization
Citations

This map shows the geographic impact of Rossella Elisei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rossella Elisei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rossella Elisei more than expected).

Fields of papers citing papers by Rossella Elisei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rossella Elisei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rossella Elisei. The network helps show where Rossella Elisei may publish in the future.

Co-authorship network of co-authors of Rossella Elisei

This figure shows the co-authorship network connecting the top 25 collaborators of Rossella Elisei. A scholar is included among the top collaborators of Rossella Elisei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rossella Elisei. Rossella Elisei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Prete, Alessandro, Liborio Torregrossa, Carla Gambale, et al.. (2025). The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma. Thyroid. 35(4). 387–396. 1 indexed citations
2.
Brose, Marcia S., Jaume Capdevila, Rossella Elisei, et al.. (2024). Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocrine Related Cancer. 31(8). 4 indexed citations
3.
Sgrò, Daniele, Piercarlo Rossi, Paolo Piaggi, et al.. (2023). Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib. Journal of the Endocrine Society. 7(8). bvad084–bvad084. 1 indexed citations
4.
Wirth, Lori J., Cosimo Durante, Duncan J. Topliss, et al.. (2022). Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. The Oncologist. 27(7). 565–572. 28 indexed citations
5.
6.
Prete, Alessandro, Antonio Matrone, Carla Gambale, et al.. (2021). Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia. Cancers. 13(21). 5554–5554. 7 indexed citations
7.
Giani, Carlotta, Laura Valerio, Alberto Bongiovanni, et al.. (2020). Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. Thyroid. 31(2). 224–232. 33 indexed citations
8.
9.
Gemignani, Federica, Cristina Romei, Raffaele Ciampi, et al.. (2020). Polymorphisms Within the RET Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma. Thyroid. 30(11). 1579–1588. 5 indexed citations
10.
Giannini, Riccardo, Clara Ugolini, Anello Marcello Poma, et al.. (2017). Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting. Thyroid. 27(10). 1267–1276. 20 indexed citations
11.
Figlioli, Gisella, Rossella Elisei, Cristina Romei, et al.. (2016). A Comprehensive Meta-analysis of Case–Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 25(4). 700–713. 17 indexed citations
12.
Schlumberger, Martin, Barbara Jarząb, Maria E. Cabanillas, et al.. (2015). A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clinical Cancer Research. 22(1). 44–53. 184 indexed citations
13.
Wells, Samuel A., L. Sylvia, Henning Dralle, et al.. (2015). Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 25(6). 567–610. 1443 indexed citations breakdown →
14.
Ugolini, Clara, Rossella Elisei, Agnese Proietti, et al.. (2013). FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment. Thyroid. 24(2). 339–346. 23 indexed citations
15.
Elisei, Rossella, Martin Schlumberger, Stefan Müller, et al.. (2013). Cabozantinib in Progressive Medullary Thyroid Cancer. Journal of Clinical Oncology. 31(29). 3639–3646. 850 indexed citations breakdown →
16.
Wells, Samuel A., Bruce G. Robinson, Robert F. Gagel, et al.. (2011). Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. 30(2). 134–141. 1082 indexed citations breakdown →
17.
Schlumberger, Martin, Rossella Elisei, Lars Bastholt, et al.. (2009). Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology. 27(23). 3794–3801. 257 indexed citations
18.
Elisei, Rossella, Clara Ugolini, David Viola, et al.. (2008). BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study. The Journal of Clinical Endocrinology & Metabolism. 93(10). 3943–3949. 401 indexed citations
19.
Elisei, Rossella, Cristina Romei, Barbara Cosci, et al.. (2007). RET Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center. The Journal of Clinical Endocrinology & Metabolism. 92(12). 4725–4729. 145 indexed citations
20.
Elisei, Rossella, Barbara Cosci, Cristina Romei, et al.. (2007). Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study. The Journal of Clinical Endocrinology & Metabolism. 93(3). 682–687. 375 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bryan R. Haugen Breakdown of academic impact, for papers by Yuri E. Nikiforov Breakdown of academic impact, for papers by James A. Fagin Breakdown of academic impact, for papers by Electron Kebebew Breakdown of academic impact, for papers by R. Michael Tuttle Breakdown of academic impact, for papers by Orlo H. Clark Breakdown of academic impact, for papers by Keith C. Bible Breakdown of academic impact, for papers by Paolo Miccoli Breakdown of academic impact, for papers by Clive S. Grant Breakdown of academic impact, for papers by Sophie Leboulleux
Rankless by CCL
2026